Literature DB >> 8017763

Leukotriene C4 formation by transcellular biosynthesis.

J Maclouf1, C Antoine, P M Henson, R C Murphy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8017763     DOI： 10.1111/j.1749-6632.1994.tb12038.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  8 in total

Review 1.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

2.  Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes.

Authors:  Tanya M Laidlaw; Molly S Kidder; Neil Bhattacharyya; Wei Xing; Shiliang Shen; Ginger L Milne; Mariana C Castells; Heng Chhay; Joshua A Boyce
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

Review 3.  The expansive role of oxylipins on platelet biology.

Authors:  Jennifer Yeung; Megan Hawley; Michael Holinstat
Journal:  J Mol Med (Berl)       Date:  2017-05-20       Impact factor: 4.599

4.  Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Anya J Cutler; Molly S Kidder; Tao Liu; Juan Carlos Cardet; Heng Chhay; Chunli Feng; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2014-01-31       Impact factor: 10.793

Review 5.  Platelets in patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2015-06       Impact factor: 10.793

Review 6.  Cysteinyl leukotriene receptors, old and new; implications for asthma.

Authors:  T M Laidlaw; J A Boyce
Journal:  Clin Exp Allergy       Date:  2012-09       Impact factor: 5.018

Review 7.  Lipid mediators and allergic diseases.

Authors:  Laura B Fanning; Joshua A Boyce
Journal:  Ann Allergy Asthma Immunol       Date:  2013-07-21       Impact factor: 6.347

8.  A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease.

Authors:  Tanya M Laidlaw; Katherine N Cahill; Juan Carlos Cardet; Katherine Murphy; Jing Cui; Brittney Dioneda; Parul Kothari; Benjamin A Raby; Elliot Israel; Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2018-06-08       Impact factor: 10.793
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.